, Tracking Stock Market Picks
Enter Symbol:
C.r. Bard, Inc. (BCR) [hlAlert]

Neutral BCR
up 29.49 %

C.r. Bard, Inc. (BCR) downgraded to Neutral by JP Morgan

Posted on: Monday,  Jan 6, 2014  8:25 AM ET by JP Morgan

JP Morgan rated Neutral C.r. Bard, Inc. (NYSE: BCR) on 01/06/2014. Previously JP Morgan rated Overweight C.r. Bard, Inc. (NYSE: BCR) on
01/02/2013., when the stock price was $99.86. Since then, C.r. Bard, Inc. has gained 29.49% as of 01/06/2014's recent price of $129.31.
If you would have followed the previous JP Morgan's recommendation on BCR, you would have gained 29.49% of your investment in 369 days.

C.R. Bard, Inc. is one of the worldwide leaders in developing, manufacturing, and supplying healthcare products that focus on Vascular, Urology, and Oncology Disease States. In addition, Bard offers a complete line of advanced Surgical Specialty products and services that address needs in hernia repair, performance irrigation, hemostasis, and other areas.

JPMorgan is a leading financial services firm with one of the largest client franchises in the world. We partner with our clients to offer the most complete and innovative solutions in the industry to help them achieve their goals. For more than 200 years, we have taken a long-term approach to our clients and to the way we conduct business. Our firm has grown considerably in scale and scope, but our commitment to our core principle of doing "only first-class business... in a first-class way" has never been stronger.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/6/2014 8:25 AM Hold
as of 10/17/2014
1 Week   
1 Month   
3 Months   
1 YTD down  -3.45 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/2/2013 8:25 AM Buy
12/15/2009 9:25 AM Buy

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy